Letteratura scientifica selezionata sul tema "Wyeth House (New York, N.Y.)"

Objective: The purpose was to identify community characteristics that contribute to reductions in readmission rates and reimbursement penalties for hospital systems in upstate New York. Methods: Hospitals in upstate NY were selected (N = 94). Using an ex post facto design and the ecological model, community characteristics of hospital systems were analyzed and coded. Independent t-tests, ANOVA, and Pearson Correlation tests were conducted. Results: Characteristicscorrelated with reduced hospital readmission rates and reimbursement penalties included hospitals (1) with critical access status; (2) located in counties with a better county health rank; and (3) located in a primary care shortage area that utilized house calls. Discussion: Implications include supporting policies that increase access to services, improve formulas for reimbursement, and encourage innovation in care delivery models. Future research efforts should focus on house calls in primary care shortage areas. Keywords: readmission rates, ecological model, house calls, community health DOI: https://doi.org/10.14574/ojrnhc.v21i1.638

Summary Feline sera were submitted to the Cornell Feline Health Center (n = 497) or to the New York State Diagnostic Laboratory (n = 1,565) for feline immunodeficiency virus (fiv) testing. Some sera (n = 166) were submitted for confirmation of previous fiv-positive results; 151 of these sera had been tested at the referring veterinary practice or laboratory, using an in-house elisa. Excluding the samples submitted for confirmation, a total of 173 samples (9.1%) were fiv-positive; 11.6% of the clinically ill or high-risk cats and 0.49% of the healthy, low risk cats were positive for fiv antibody. A commercially available elisa for detection of antibody to fiv was evaluated in relation to the immunofluorescent antibody (ifa) test and the immunoblot assay. The elisa was interpreted according to the manufacturer's instructions, with the ratio of sample optical density to positive control optical density (s/p) determining a positive or negative result. The elisa results based on the s/p interpretation were compared with a kinetics-based (kela) interpretation of the elisa. The kela values were reported as positive, negative, or equivocal. Using the immunoblot as the standard, elisa (s/p interpretation) had sensitivity of 0.93 and specificity of 0.98, whereas the ifa test had sensitivity of 0.95 and specificity of 0.98. However, the sensitivity and specificity of the elisa (s/p interpretation) were markedly reduced for sample results falling in the kela equivocal range, indicating that equivocal results were valid interpretations for some sera. A high number (22.5%) of the samples submitted for confirmation of a positive result from use of the in-house elisa were determined to be negative for fiv antibody. Operator error or incorrect interpretation of the in-house elisa were thought to be the cause of most of these false-positive test results.

Heinrich Detering, Was heißt hier “wir”? Zur Rhetorik der parlamentarischen Rechten (Dietzingen: Reclam Press, 2019).Clare Copley, Nazi Buildings: Cold War Traces and Governmentality in Post-Unification Berlin (London: Bloomsbury Academic, 2020).Tobias Schulze-Cleven and Sidney A. Rothstein, eds., Imbalance: Germany’s Political Economy after the Social Democratic Century (Abingdon: Routledge, 2021).Benedikt Schoenborn, Reconciliation Road: Willy Brandt, Ostpolitik and the Quest for European Peace (New York: Berghahn Books, 2020).Tiffany N. Florvil, Mobilizing Black Germany: Afro-German Women and the Making of a Transnational Movement (Champaign: University of Illinois Press, 2020).Ingo Cornils, Beyond Tomorrow: German Science Fiction and Utopian Thought in the 20th and 21st Centuries (Rochester, NY: Camden House, 2020).Christian F. Ostermann, Between Containment and Rollback: The United States and the Cold War in Germany (Stanford, CA: Stanford University Press, 2021).

Background:Axial spondyloarthritis (axSpA) is an inflammatory disease characterised by chronic back pain, and it comprises radiographic axSpA and non-radiographic axSpA (nr-axSpA).1 Secukinumab (SEC) 150 mg, with (LD) or without loading (NL), dose significantly improved the signs and symptoms of patients with nr-axSpA in the PREVENT (NCT02696031) study through Week 52.2Objectives:To report the long-term clinical efficacy and safety of secukinumab from the PREVENT study through 2 years.Methods:A detailed study design, key primary and secondary endpoints have been reported previously.2 In total, 555 patients fulfilling ASAS criteria for axSpA plus abnormal C-reactive protein (CRP) and/or MRI, without evidence of radiographic changes in sacroiliac (SI) joints according to modified New York Criteria for AS were randomised (1:1:1) to receive SEC 150 mg with LD, NL, or placebo (PBO) at baseline. LD patients received SEC 150 mg at Weeks 1, 2, 3, and 4, and then every 4 weeks (q4wk) starting at Week 4. NL patients received SEC 150 mg at baseline and PBO at weeks 1, 2, and 3, and then 150 mg q4wk. 90% patients were anti-tumour necrosis factor (anti-TNF) naïve, 57% had elevated CRP and 73% had evidence of SI joint inflammation on MRI. All images were assessed centrally before inclusion. All patients continued to receive open-label SEC 150 mg treatment after Week 52. Efficacy assessments through Week 104 included ASAS40 in anti-TNF-naïve patients, ASAS40, BASDAI change from baseline, BASDAI50, ASAS partial remission, and ASDAS-CRP inactive disease in the overall population. The safety analyses included all patients who received ≥1 dose of study treatment for the entire treatment period up to Week 104. Data are presented as observed.Results:Overall, 438 patients completed 104 weeks of study: 78.9% (146/185; LD), 77.7% (143/184; NL) and 80.1% (149/186; PBO). Efficacy results at Week 52 were sustained through Week 104 and are reported in the Table 1. The safety profile was consistent with the previous reports with no deaths reported during the entire treatment period up to Week 104.2Conclusion:Secukinumab 150 mg demonstrated sustained improvement in the signs and symptoms of patients with nr-axSpA through 2 years. Secukinumab was well tolerated with no new or unexpected safety signals.References:[1]Strand V, et al. J Clin Rheumatol. 2017; 23(7):383–91.[2]Deodhar A, et al. Arthritis Rheumatol. 2020. Online ahead of print.Figure 1.ASAS40 response was maintained through Week 104 in the overall populationTable 1.Summary of clinical efficacy (Observed data)EndpointsWeekSEC 150 mg LD(N=185)SEC 150 mg NL(N=184)PBO-SEC 150 mg(N=186)*ASAS40 in anti-TNF-naïve patients, n/M (%)52a90/137 (65.7)95/145 (65.5)85/151 (56.3)10478/123 (63.4)83/123 (67.5)83/134 (61.9)BASDAI change from baseline, mean±SD52a−3.7±2.8−3.7±2.6−3.3±2.4104−4.1±2.6−3.9±2.6−3.7±2.5BASDAI50, n/M (%)52a90/153 (58.8)92/163 (56.4)90/161 (55.9)10488/137 (64.2)84/136 (61.8)87/142 (61.3)ASAS partial remission,n/M (%)52a46/152 (30.3)56/163 (34.4)46/161 (28.6)10451/137 (37.2)50/135 (37.0)50/142 (35.2)ASDAS CRP inactive disease, n/M (%)52a49/152 (32.2)58/163 (35.6)48/160 (30.0)10450/132 (37.9)53/133 (39.8)53/142 (37.3)*For anti-TNF-naïve patients, N=164, LD; 166, NL; 171, PBO-SEC.a total number of evaluable patients including open-label SEC and standard of care (SOC; 2 patients in LD, 1 patient in NL continued on SOC). After Week 52, only patients who continued to receive open-label SEC are presented.ASAS, Assessment of SpondyloArthritis International Society; ASDAS, Ankylosing Spondylitis Disease Activity Score; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; M, number of patients with evaluation; N, total randomised patients; n, number of patients who are responders; SD, standard deviationDisclosure of Interests:Denis Poddubnyy Speakers bureau: AbbVie, BMS, Eli Lilly, MSD, Novartis, Pfizer, UCB, Consultant of: AbbVie, Biocad, BMS, Eli Lilly, Gilead, MSD, Novartis, Pfizer, Samsung Bioepis, UCB, Grant/research support from: AbbVie, MSD, Novartis, Pfizer, Atul Deodhar Speakers bureau: AbbVie, Amgen, Boehringer Ingelheim, Bristol Myer Squibb (BMS), Eli Lilly, GSK, Janssen, Novartis, Pfizer, and UCB, Consultant of: AbbVie, Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Eli Lilly, Gilead, GSK, Janssen, Novartis, Pfizer, and UCB, Grant/research support from: AbbVie, Eli Lilly, GSK, Novartis, Pfizer, and UCB, Xenofon Baraliakos Speakers bureau: AbbVie, BMS, Celgene, Chugai, MSD, Novartis, Pfizer, and UCB, Consultant of: AbbVie, BMS, Celgene, Chugai, Galapagos, Gilead, MSD, Novartis, Pfizer, and UCB, Grant/research support from: AbbVie and Novartis, Ricardo Blanco Speakers bureau: AbbVie, Pfizer, Roche, Bristol-Myers, Janssen, UCB pharma and MSD and Eli Lilly, Consultant of: AbbVie, Pfizer, Roche, Bristol-Myers, Janssen, UCB pharma and MSD, Grant/research support from: AbbVie, MSD, and Roche, Eva Dokoupilova Grant/research support from: AbbVie, Affibody AB, Eli Lilly, Galapagos, Gilead, GSK, Hexal AG, MSD, Novartis, Pfizer, R-Pharm, Sanofi-Aventis, and UCB, Stephen Hall Speakers bureau: Novartis, Merck, Janssen, Pfizer, Eli Lilly, and UCB, Consultant of: Novartis, Merck, Janssen, Pfizer, Eli Lilly, and UCB, Grant/research support from: AbbVie, UCB, Janssen, and Merck, Alan Kivitz Shareholder of: Pfizer, Sanofi, Novartis, Amgen, GlaxoSmithKline, Gilead Sciences, Inc., Speakers bureau: Celgene, GlaxoSmithKline, Eli Lilly, Merck, Novartis, Pfizer, Sanofi, Genzyme, Flexion, AbbVie, UCB, Consultant of: AbbVie, Boehringer Ingelheim, Flexion, Janssen, Pfizer, Sanofi, Regeneron, SUN Pharma Advanced Research, Gilead Sciences, Inc., Marleen G.H. van de Sande Speakers bureau: Novartis, MSD, Consultant of: Abbvie, Novartis, Eli Lily, Grant/research support from: Novartis, Eli Lilly, Janssen, UCB, Anna Stefanska Shareholder of: Novartis, Employee of: Novartis, Patricia Pertel Shareholder of: Novartis, Employee of: Novartis, Hanno Richards Shareholder of: Novartis, Employee of: Novartis, Juergen Braun Speakers bureau: Abbvie (Abbott), Amgen, BMS, Boehringer, Celgene, Celltrion, Centocor, Chugai, EBEWE Pharma, Medac, MSD (Schering-Plough), Mundipharma, Novartis, Pfizer (Wyeth), Roche, Sanofi-Aventis and UCB pharma, Eli Lilly, Consultant of: Abbvie (Abbott), Amgen, BMS, Boehringer, Celgene, Celltrion, Centocor, Chugai, EBEWE Pharma, Medac, MSD (Schering-Plough), Mundipharma, Novartis, Pfizer (Wyeth), Roche, Sanofi-Aventis and UCB, Eli Lilly, Grant/research support from: Abbvie (Abbott), Amgen, BMS, Boehringer, Celgene, Celltrion, Centocor, Chugai, Medac, MSD (Schering-Plough), Mundipharma, Novartis, Pfizer (Wyeth), Roche, Sanofi-Aventis and UCB, Eli Lilly

Globally, sex workers have highlighted the harms that accompany anti-prostitution efforts advanced via anti-trafficking policy, and there is a growing body of social science research that has emerged documenting how anti-trafficking efforts contribute to carceral and sexual humanitarian interventions. Yet mounting evidence on the harms of anti-trafficking policies has done little to quell the passage of more laws, including policies aimed at stopping sexual exploitation facilitated by technology. The 2018 passage of the Allow States and Victims to Fight Online Sex Trafficking Act (FOSTA) in the U.S. House of Representatives, and the corresponding Senate bill, the Stop Enabling Sex Traffickers Act (SESTA), is a case study in how efforts to curb sexual exploitation online actually heighten vulnerabilities for the people they purport to protect. Drawing on 34 months of ethnographic fieldwork and interviews with sex workers and trafficked persons (n = 58) and key informants (n = 20) in New York and Los Angeles, we analyze FOSTA/SESTA and its harmful effects as a launchpad to more broadly explore how technology, criminalization, shifting governance arrangements, and conservative moralities cohere to exacerbate sex workers’ vulnerability.

Background:Current demographic data predict that the number of older adults with rheumatic diseases will considerably increase in the coming years. Geriatric patients differ from younger adults in many ways including their clinical presentation, co-morbidities and response to medication. The management of such patients is often challenging due to the presence of multi-morbidity, polypharmacy and geriatric syndromes (i.e. conditions in which symptoms result from impairments in multiple systems rather than a discrete disease). To systematically assess geriatric patients, specific tools have been developed; however, they are not routinely utilized by rheumatologists. Using these tools could improve patient management and satisfaction in rheumatologic care.Objectives:To examine the prevalence of 17 common geriatric health problems using validated geriatric assessment tools in older patients with rheumatic and musculoskeletal diseases.Methods:Adults 65 years and older who presented to a tertiary rheumatologic hospital were included after informed consent. All patients recruited were assessed using theMAngableGeriatrICAssessment (MAGIC) which addresses 14 common geriatric health problems. In addition, polypharmacy (≥ 5 medication), muscle function using the Short Physical Performance Battery and frailty applying the Fried definition were assessed. Disability was quantified with the “Funktionsfragebogen Hannover” (FFbH), a validated tool for patients with rheumatologic diseases that can be easily converted to Health Assessment Questionnaire (HAQ) scores. Primary outcome was the frequency of the selected 17 geriatric health problems; the correlation of the total number of problems with HAQ scores was a secondary outcome.Results:Of the 300 individuals included 67% were female with a mean age of 73±6.6 years; 85% (> 50% with rheumatoid arthritis) had a rheumatologic diagnosis. The remaining participants had either a chronic pain syndrome or degenerative joint/spine disease. On average participants had 7 out of 17 assessed geriatric problems. Females had more such problems than males (8 vs. 6, p<0.0001). Chronic pain and polypharmacy were most common but several others were also seen in more than 50% of patients (see Table). The mean HAQ Score was 1.67±0.79. There was a positive correlation (see Graph) between the number of problems and the HAQ Score (R2= 0.44, p<0.0001).Conclusion:A systematic geriatric assessment can be successfully used to discover and quantify geriatric health problems in older patients with rheumatic and musculoskeletal diseases. These problems appear to be very common and importantly, patients with more problems had poorer functional status. Frailty, depression, incomplete vaccination status, cognitive impairment or polypharmacy are all known to negatively impact patient care. Recognizing and addressing geriatric problems has the potential to lead to health care improvements including adherence and medication side effects and might increase patient satisfaction and functional status independent of disease activity.References:[1]Buehring, B. and S. Barczi, Assessing the Aging Patient, in Spine Surgery in an Aging Population, N. Brooks and A. Strayer, Editors. 2019, Thieme: New York. p. 208.[2]Cleutjens F, Boonen A, van Onna MGB. Geriatric syndromes in patients with rheumatoid arthritis: a literature overview. Clin Exp Rheumatol 2019;37(3):496-501Geriatric Problem% presentProblems with Daily Activities67Problems with Vision28Problems with Hearing38Problems with Falls11Problems with Urinary Incontinence38Problems with Depression57Lack of Social Support10Incomplete Vaccinations53Problems with Cognition31Problems with Chronic Pain90Problems with Dizziness44Problems with Mobility41Problems with Unintentional Weight Loss30Inappropriate Medications present17Polypharmacy present81Frailty present46Short Physical Performance Battery low57Acknowledgments:NoneDisclosure of Interests:Anna Berrisch: None declared, Ioana Andreica: None declared, Styliani Tsiami: None declared, David Kiefer Grant/research support from: Novartis, Uta Kiltz Grant/research support from: AbbVie, Amgen, Biogen, Novartis, Pfizer, Consultant of: AbbVie, Biocad, Eli Lilly and Company, Grünenthal, Janssen, Novartis, Pfizer, UCB, Speakers bureau: AbbVie, MSD, Novartis, Pfizer, Roche, UCB, Xenofon Baraliakos Grant/research support from: Grant/research support from: AbbVie, BMS, Celgene, Chugai, Merck, Novartis, Pfizer, UCB and Werfen, Consultant of: AbbVie, BMS, Celgene, Chugai, Merck, Novartis, Pfizer, UCB and Werfen, Speakers bureau: AbbVie, BMS, Celgene, Chugai, Merck, Novartis, Pfizer, UCB and Werfen, Juergen Braun Grant/research support from: Abbvie (Abbott), Amgen, BMS, Boehringer, Celgene, Celltrion, Centocor, Chugai, Eli Lilly and Company, Medac, MSD (Schering Plough), Mundipharma, Novartis, Pfizer (Wyeth), Roche, Sanofi- Aventis, and UCB Pharma, Consultant of: Abbvie (Abbott), Amgen, BMS, Boehringer, Celgene, Celltrion, Centocor, Chugai, EBEWE Pharma, Eli Lilly and Company, Medac, MSD (Schering-Plough), Mundipharma, Novartis, Pfizer (Wyeth), Roche, Sanofi-Aventis, and UCB Pharma, Speakers bureau: Abbvie (Abbott), Amgen, BMS, Boehringer, Celgene, Celltrion, Centocor, Chugai, EBEWE Pharma, Eli Lilly and Company, Medac, MSD (Schering-Plough), Mundipharma, Novartis, Pfizer (Wyeth), Roche, Sanofi-Aventis, and UCB Pharma, Bjoern Buehring Grant/research support from: GE/Lunar, Kinemed, Consultant of: Gilead, Abbvie, Lilly, GE/Lunar, Janssen, Amgen, Speakers bureau: UCB

A house is a place where we all aspire to cherish quality time with our family. It is believed that a house functions as a home, where one spends most of the life-creating memorable moments with friends and family. With the rapid increase in world population, there has been a surge in the demand for housing space. As more and more individuals are in search of affordable and multipurpose space, it becomes even more important to design a house with a relaxing, pleasant, and aesthetically appealing interior (Husein, 2021). Today’s society is affected by urbanization, which is resulting in an increased demand for housing in the cities, lending to higher marketing prices and smaller apartments. There is a rise in the number of people struggling in present societies due to the increased population and urbanization. More people are drawn towards living in cities, which causes a rise in the number of small spaces (Urist, 2013). According to Doshi, (2019), people living in small houses face various difficulties such as the lack of clearance space, unorganized furniture arrangements, lack of storage space, improper selection of size-wise furniture which could make the room look smaller, the colour of the walls can also make the house look unpleasant, and low ceiling gives an illusion of shorter and bulkier room. Thus, to utilize the space available in the most beautiful way and with the least possible error, proper guidance is of utmost importance. Keywords : Cite : References : Desai, N. (2023). Designing Multipurpose Furniture for Small Spaces using a Combination of Interior Materials. Vadodara: Published Ph.D. Thesis. Doshi, N. (2019). Design Development and Space Utilization of selected Small Houses in Vadodara city. Vadodara: Unpublished Master's Thesis. Gandotra, V., & Patel, S. (2006). Housing for Family Living. Vadodara: Dominant Publishers and Distributors. Gauer, J. (2004). The new American dream: Living well in small homes. New York: The Monacelli Press, Inc. Husein, H. A. (2021). Multifunctional Furniture as a Smart Solution for Small Spaces for the Case of Zaniary Towers Apartments in Erbil City, Iraq. International Transaction Journal of Engineering, Management, & Applied Sciences & Technologies, 12(1), 12A1H, 1-11. http://TUENG Rangwala, S. (2015). Building Construction. Anand, Gujarat, India: Charotar Publishing House. Rao, R. (2018). Ergonomic Evaluation of Residences (External Areas and Living Room) of the Elderly. International Journal of Research Culture Society. Vol 2, Issue 4, Apr 2018 pp.320 – 330. (201804063.pdf (ijrcs.org) Suman Singh (2007) Ergonomic Interventions for Health and Productivity. Himanshu Publications, Udaipur. ISBN: 81-7906-148-5. Susanka, S. (2000). Creating the not-so-big house: Insights and ideas for the new American home. The Taunton Press, Inc. T. (2014, August 21). Are tiny houses and micro-apartments the future of urban homes? https://www.theguardian.com/: Urist, J. (2013, December 19). The Health Risks of Small Apartments Living in tiny spaces can cause psychological problems. https://www.theatlantic.com/health/archive/2013/12/the-health-risks-of-small-apartments/282150/ Wilhide, E. (2008). Small spaces: Maximizing limited spaces for living. London, England: Jacqui Small LLP.

Roberta Gironi Departamento de Proyectos Arquitectónicos, UPV. Camino de Vera, s/n. 46022 Valencia Joint Doctorate Dipartimento di Architettura – Teorie e Progetto. “Sapienza” Università degli Studi di Roma. Via Gramsci, 53. 00100 Roma E-mail: roberta.gironi@gmail.com Keywords (3-5): Informal processes, dynamic transformation, new planning approach, flexible space, self-organization Conference topics and scale: Reading and regenerating the informal city Contemporary cities are affected by transformations that put in discussion the claim of control and stability to which the urban project aspires. All those gradual adjustments are manifested according to the demand, bring toward a less formal and more flexible spatial order, for which the traditional forms of the "static" city become the background of the "kinetic" landscape of informal cities. On the contrary of the formal processes of urban planning, informality process is configured as an organic development model and a flexible dynamic system opened to changes. The informal space is produced according to principles of spontaneity and self-organization. A consideration on the possibility to assume different approaches can be proposed. Those approaches should integrate in the design reasoning all the dynamics usually excluded by the discourse on the urban project, which processes can become catalysts to enrich the methods of planning and design of the urban space. Through the analysis of the case-study Previ Lima and the Living Room at the Border of St. Ysidro, the aim is to delineate in which way the contemporary architecture can absorb and metabolize these processes, triggering a different approach to a different method to intervene in the spaces of relationship among formal and informal. It is believed that the informal urban qualities cannot be eliminated and is impossible to ignore the inhabitants' practices, but rather to work on the intersection between collective and individual actions. References Brillembourg A., Feireiss K., Klumpner H. (2005), Informal City (Prestel Publishing, Munich) Cruz T. (2008), "De la frontière globale au quartier de frontière: pratiques d'empiètement", Multitudes, 31(1). Davis M. (2006), Planet of Slums (Verso, London). Hernandez F., Kellett P., Allen L.K. (2010), Rethinking the informal city: critical perspectives from Latin America (Berghahn books, New York, Oxford). McFarlane C., Waibel M., (2012), Urban Informalities: Reflections on the Formal and Informal (Ashgate, Farnham). Jacobs J. (1961), The death and life of great American cities(Random House, New York- Toronto). Roy A., Alsayyad N., (2004) Urban Informality: Transnational Perspectives from the Middle East, Latin America, and South Asia (Lexington Books, Lanham)